Literature DB >> 1606674

Allergic ocular disorders: a spectrum of diseases.

W H Ehlers1, P C Donshik.   

Abstract

Allergic eye disease is commonly encountered in clinical practice. The external eye is exposed to a host of environmental, cosmetic, and pharmacologic antigens. Although individual responses show a wide range of variability, a number of distinctive syndromes have emerged to define the spectrum of allergic eye disease. They consist of seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC), giant papillary conjunctivitis (GPC), and contact allergies involving the conjunctiva.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606674

Source DB:  PubMed          Journal:  CLAO J        ISSN: 0733-8902


  8 in total

Review 1.  Allergic eye disease mechanisms.

Authors:  J I McGill; S T Holgate; M K Church; D F Anderson; A Bacon
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

2.  Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.

Authors:  Veysi Oner; Fatih Mehmet Türkcü; Mehmet Taş; Mehmet Fuat Alakuş; Yalçın Işcan
Journal:  Jpn J Ophthalmol       Date:  2012-05-25       Impact factor: 2.447

3.  γδ T cells are required for maximal expression of allergic conjunctivitis.

Authors:  Nancy J Reyes; Elizabeth Mayhew; Peter W Chen; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-06       Impact factor: 4.799

Review 4.  Ocular allergies.

Authors:  L Fonacier; J Luchs; I Udell
Journal:  Curr Allergy Asthma Rep       Date:  2001-07       Impact factor: 4.806

5.  A double blind placebo controlled group comparative study of ophthalmic sodium cromoglycate and nedocromil sodium in the treatment of vernal keratoconjunctivitis.

Authors:  M el Hennawi
Journal:  Br J Ophthalmol       Date:  1994-05       Impact factor: 4.638

6.  Allergic conjunctivitis.

Authors:  Varsha M Rathi; Somasheila I Murthy
Journal:  Community Eye Health       Date:  2017

7.  Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model.

Authors:  Edward J Meier; Gail L Torkildsen; Paul J Gomes; Mark C Jasek
Journal:  Clin Ophthalmol       Date:  2018-12-13

8.  Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects.

Authors:  Ranjan P Malhotra; Edward Meier; Gail Torkildsen; Paul J Gomes; Mark C Jasek
Journal:  Clin Ophthalmol       Date:  2019-02-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.